Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $17.4 million.

  • Spero Therapeutics' Cash from Operations rose 3650.4% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year decrease of 5781.25%. This contributed to the annual value of -$23.4 million for FY2024, which is 2894.68% up from last year.
  • Per Spero Therapeutics' latest filing, its Cash from Operations stood at $17.4 million for Q3 2025, which was up 3650.4% from -$17.7 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Cash from Operations registered a high of $44.5 million during Q4 2022, and its lowest value of -$28.2 million during Q1 2022.
  • In the last 5 years, Spero Therapeutics' Cash from Operations had a median value of -$15.5 million in 2021 and averaged -$7.0 million.
  • As far as peak fluctuations go, Spero Therapeutics' Cash from Operations soared by 176300.94% in 2023, and later crashed by 16739.64% in 2025.
  • Quarter analysis of 5 years shows Spero Therapeutics' Cash from Operations stood at -$27.3 million in 2021, then soared by 262.65% to $44.5 million in 2022, then crashed by 139.33% to -$17.5 million in 2023, then crashed by 33.77% to -$23.4 million in 2024, then soared by 174.45% to $17.4 million in 2025.
  • Its Cash from Operations was $17.4 million in Q3 2025, compared to -$17.7 million in Q2 2025 and -$4.0 million in Q1 2025.